The Effect of BIM Deletion Polymorphism on Intrinsic Resistance and Clinical Outcome of Cancer Patient with Kinase Inhibitor Therapy

Hou-Qun Ying,Jie Chen,Bang-Shun He,Yu-Qin Pan,Feng Wang,Qi-Wen Deng,Hui-Ling Sun,Xian Liu,Shu-Kui Wang
DOI: https://doi.org/10.1038/srep11348
IF: 4.6
2015-01-01
Scientific Reports
Abstract:A common deletion polymorphism within B-cell chronic lymphocytic leukemia-lymphoma like 11 gene ( BIM ) was deemed to be a genetic cause leading to compromised kinase inhibitor therapeutic efficacy in cancer individuals. However, the results reported were not consistent. Thus, a comprehensive meta-analysis containing 12 eligible studies including 1,532 Asian patients was conducted to investigate a steady and reliable conclusion. The results showed that BIM deletion polymorphism was significantly associated with tyrosine kinase inhibitor (TKI) clinical efficacy in term of response rate ( P h = 0.349, HR = 0.438, 95%CI = 0.274–0.699) and disease control rate ( P h = 0.941, HR = 0.370, 95%CI = 0.202–0.678) in EGFR -mutated NSCLC population, not in CML and HCC subgroups. Additionally, EGFR -mutated NSCLC patient harbored BIM deletion polymorphism was associated with a shorter progression-free survival (PFS) than those with BIM wild polymorphism ( P h = 0.580, adjusted HR = 2.194, 95%CI = 1.710–2.814). However, no significant association was examined between BIM deletion polymorphism and overall survival (OS) and toxic adverse events in EGFR -mutated NSCLC population and it was not associated with PFS and OS in HCC subgroup. These findings revealed that BIM deletion polymorphism might be a genetic cause of intrinsic resistance to TKI therapy and it could be emerged as an independent predictor to identify patients who would benefit from TKI targeted therapy in EGFR -mutated NSCLC.
What problem does this paper attempt to address?